News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ACC 2018 Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis Michael O'Riordan March 14, 2018
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2018 SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients Michael O'Riordan March 11, 2018
News Conference News ACC 2018 ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More Shelley Wood March 11, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018